Antibody Therapy Prevents Diabetes in Mice

Investigators have effectively prevented the onset of type 1 diabetes in laboratory mice prone to developing the disease using an antibody against a receptor on the surface of immune T-cells.

According to the investigators, from the University of Pittsburgh (Pitt; PA, USA), these results, which were published in the January 2007, issue of the journal Diabetes, have significant implications for the prevention of type 1 diabetes.

Type 1 diabetes is an autoimmune disorder in which the body errantly attacks the insulin-producing cells of the pancreas, causing chronically elevated levels of glucose in the blood, which can lead to blindness, kidney failure, heart disease, and nerve damage. Previously known as juvenile diabetes, type 1 diabetes is typically diagnosed at a very early age, but in some instances it can be diagnosed in adult hood.

In this study, the Pitt researchers treated non-obese diabetic (NOD) mice with an antibody--a type of protein generated by the immune system that recognizes and helps combat infections and other foreign substances in the body--directed against a receptor known as CD137 on the surface of a type of immune cell called T-cells. Treating NOD mice with the anti-CD137 antibodies considerably inhibited the development of diabetes, whereas most of the control mice developed diabetes by the time they were six months old. Surprisingly, the antibody therapy did not appear to cure the NOD mice because the researchers were still able to see lymphocytes in their pancreatic islets, a characteristic sign of pancreatic inflammation and autoimmunity. Furthermore, when the researchers isolated cells from the spleens of the antibody-treated mice and injected these cells into immune-deficient NOD mice, seven of the nine recipient mice developed type 1 diabetes, indicating that the donor mice still harbored pathogenic T-cells. However, when the researchers transferred a specific subset of T-cells from anti-CD137-treated mice that expressed two other receptors known as CD4 and CD25 to other immune-deficient NOD mice, it prevented the onset of diabetes in the recipient mice.

According to senior author William M. Ridgway, M.D., assistant professor in the University of Pittsburgh, School of Medicine's department of rheumatology and clinical immunology, this therapy, if given early enough, may offer an effective method for preventing the onset of type 1 diabetes in genetically at-risk individuals.

"Our studies and others suggest that CD137 plays a significant role in the development of and genetic predisposition to type 1 diabetes. In this study, for the first time, we have demonstrated that CD137 antibody therapy can suppress the development of type 1 diabetes in mice and that the effect is dependent on the induction of a certain subset of regulatory T-cells. If we can demonstrate this same genetic predisposition and therapeutic effect in human type 1 diabetes patients, then this may prove to be a significant step toward preventing this disease before it can take hold,” he explained.



Related Links:
University of Pittsburgh